Malaysia · Delayed Price · Currency is MYR Pharmaniaga Berhad Statistics
Total Valuation
KLSE:PHARMA has a market cap or net worth of MYR 1.93 billion. The enterprise value is 2.52 billion.
| Market Cap | 1.93B |
| Enterprise Value | 2.52B |
Important Dates
The last earnings date was Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KLSE:PHARMA has 6.56 billion shares outstanding. The number of shares has increased by 150.74% in one year.
| Current Share Class | 6.56B |
| Shares Outstanding | 6.56B |
| Shares Change (YoY) | +150.74% |
| Shares Change (QoQ) | +37.83% |
| Owned by Insiders (%) | 1.11% |
| Owned by Institutions (%) | 11.04% |
| Float | 2.44B |
Valuation Ratios
The trailing PE ratio is 22.02 and the forward PE ratio is 15.95.
| PE Ratio | 22.02 |
| Forward PE | 15.95 |
| PS Ratio | 0.49 |
| PB Ratio | 4.21 |
| P/TBV Ratio | 5.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.07, with an EV/FCF ratio of -53.09.
| EV / Earnings | 51.95 |
| EV / Sales | 0.64 |
| EV / EBITDA | 16.07 |
| EV / EBIT | 19.44 |
| EV / FCF | -53.09 |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 1.79.
| Current Ratio | 0.91 |
| Quick Ratio | 0.46 |
| Debt / Equity | 1.79 |
| Debt / EBITDA | 5.23 |
| Debt / FCF | -17.27 |
| Interest Coverage | 2.11 |
Financial Efficiency
Return on equity (ROE) is 32.36% and return on invested capital (ROIC) is 8.30%.
| Return on Equity (ROE) | 32.36% |
| Return on Assets (ROA) | 3.82% |
| Return on Invested Capital (ROIC) | 8.30% |
| Return on Capital Employed (ROCE) | 20.39% |
| Weighted Average Cost of Capital (WACC) | 8.31% |
| Revenue Per Employee | 1.12M |
| Profits Per Employee | 13,852 |
| Employee Count | 3,502 |
| Asset Turnover | 1.85 |
| Inventory Turnover | 5.24 |
Taxes
In the past 12 months, KLSE:PHARMA has paid 24.05 million in taxes.
| Income Tax | 24.05M |
| Effective Tax Rate | 32.18% |
Stock Price Statistics
The stock price has increased by +31.11% in the last 52 weeks. The beta is 0.99, so KLSE:PHARMA's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | +31.11% |
| 50-Day Moving Average | 0.29 |
| 200-Day Moving Average | 0.25 |
| Relative Strength Index (RSI) | 47.52 |
| Average Volume (20 Days) | 61,091,865 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:PHARMA had revenue of MYR 3.93 billion and earned 48.51 million in profits. Earnings per share was 0.01.
| Revenue | 3.93B |
| Gross Profit | 409.16M |
| Operating Income | 129.65M |
| Pretax Income | 74.74M |
| Net Income | 48.51M |
| EBITDA | 156.83M |
| EBIT | 129.65M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 258.57 million in cash and 819.79 million in debt, with a net cash position of -561.22 million or -0.09 per share.
| Cash & Cash Equivalents | 258.57M |
| Total Debt | 819.79M |
| Net Cash | -561.22M |
| Net Cash Per Share | -0.09 |
| Equity (Book Value) | 459.16M |
| Book Value Per Share | 0.12 |
| Working Capital | -146.85M |
Cash Flow
In the last 12 months, operating cash flow was -17.69 million and capital expenditures -29.78 million, giving a free cash flow of -47.47 million.
| Operating Cash Flow | -17.69M |
| Capital Expenditures | -29.78M |
| Free Cash Flow | -47.47M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 10.42%, with operating and profit margins of 3.30% and 1.24%.
| Gross Margin | 10.42% |
| Operating Margin | 3.30% |
| Pretax Margin | 1.90% |
| Profit Margin | 1.24% |
| EBITDA Margin | 3.99% |
| EBIT Margin | 3.30% |
| FCF Margin | n/a |
Dividends & Yields
KLSE:PHARMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -150.74% |
| Shareholder Yield | -150.74% |
| Earnings Yield | 2.51% |
| FCF Yield | -2.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 5, 2021. It was a forward split with a ratio of 5.
| Last Split Date | Jul 5, 2021 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
KLSE:PHARMA has an Altman Z-Score of 2.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.22 |
| Piotroski F-Score | 4 |